Takeda (Japan)

本机构学者在这里署名、按本站篇数

合作机构同一篇文章里的其他机构

1. University of North Carolina at Chapel Hill美国2
2. Takeda (United States)美国2
3. Kawasaki Medical School日本2
4. Teikyo University日本1
5. Janssen Research & Development (United States)美国1
6. Shiga University of Medical Science日本1
7. Rutgers, The State University of New Jersey美国1
8. Takeda (United Kingdom)英国1

按月发文

逐年被引

最新文献

1. 1
   Identifying the Initiation of a New Line of Therapy for Metastatic Lung, Breast, and Colorectal Cancer in Real‐World Data: A Scoping ReviewPharmacoepidemiology and Drug Safety20260
2. 2
   Long-term safety and effectiveness of vonoprazan as maintenance therapy for reflux esophagitis in Japan: a 12-month post-marketing surveillance studyExpert Opinion on Drug Safety20261
3. 3
   Real-world safety and effectiveness of intravenous fomepizole in patients with ethylene glycol and methanol poisoning in Japan: results of a 7-year post-marketing surveillance studyExpert Opinion on Drug Safety20243
4. 4
   Safety and effectiveness of rasagiline in patients with Parkinson’s disease in Japan: a post-marketing surveillance studyExpert Opinion on Drug Safety20236
5. 5
   Long-term safety and effectiveness of vonoprazan for prevention of gastric and duodenal ulcer recurrence in patients on nonsteroidal anti-inflammatory drugs in Japan: a 12-month post-marketing surveillance studyExpert Opinion on Drug Safety20228
6. 6
   Effect of omega-3 fatty acids on cardiovascular events in high-risk patients with hypertriglyceridemia in Japan: a 3-year post-marketing surveillance study (OCEAN3 survey)Expert Opinion on Drug Safety20221
7. 7
   Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes MellitusDrug Safety201937
8. 8
   The safety and effectiveness of vonoprazan-basedHelicobacter pylorieradication therapy; a prospective post-marketing surveillanceExpert Opinion on Drug Safety201919
9. 9
   Correction to: Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial ExperienceDrug Safety20184
10. 10
    Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial ExperienceDrug Safety201847

高被引文献

1. 1
   Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial ExperienceDrug Safety201847
2. 2
   Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes MellitusDrug Safety201937
3. 3
   Epidemiology of lactic acidosis in type 2 diabetes patients with metformin in JapanPharmacoepidemiology and Drug Safety201625
4. 4
   The safety and effectiveness of vonoprazan-basedHelicobacter pylorieradication therapy; a prospective post-marketing surveillanceExpert Opinion on Drug Safety201919
5. 5
   Long-term safety and effectiveness of vonoprazan for prevention of gastric and duodenal ulcer recurrence in patients on nonsteroidal anti-inflammatory drugs in Japan: a 12-month post-marketing surveillance studyExpert Opinion on Drug Safety20228
6. 6
   Safety and effectiveness of rasagiline in patients with Parkinson’s disease in Japan: a post-marketing surveillance studyExpert Opinion on Drug Safety20236
7. 7
   Correction to: Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial ExperienceDrug Safety20184
8. 8
   Real-world safety and effectiveness of intravenous fomepizole in patients with ethylene glycol and methanol poisoning in Japan: results of a 7-year post-marketing surveillance studyExpert Opinion on Drug Safety20243
9. 9
   Post‐marketing surveillance in Japan: Potential best way forwardPharmacoepidemiology and Drug Safety20171
10. 10
    Effect of omega-3 fatty acids on cardiovascular events in high-risk patients with hypertriglyceridemia in Japan: a 3-year post-marketing surveillance study (OCEAN3 survey)Expert Opinion on Drug Safety20221

主要发表期刊